Association of a CCB-Related Pharmacogenomics-Guided Strategy with Blood Pressure Outcomes and Short-Term Safety in Chinese Patients with Hypertension: A Secondary Exploratory Analysis of Two Randomized Cohorts.

Antihypertensive prescribing strategy guided by CACNA1C rs2238032 and CYP3A5 rs776746 genotypes in patients receiving a calcium channel blocker-containing regimen.

Calcium channel blockers show notable interindividual variability in antihypertensive response. This secondary exploratory analysis included patients receiving calcium channel blocker-containing regimens from two completed multicentre randomised cohorts, one in Hunan (4,608 patients, a genotype-guided strategy combined with structured management over 4 weeks) and one in Fujian (418 patients, genotype-guided treatment from week 4 to week 8 after an initial standardised management phase), based on CACNA1C rs2238032 and CYP3A5 rs776746. In the Hunan cohort the genotype-guided group achieved better blood pressure control at 4 weeks (81.83% versus 25.07%; adjusted OR 14.56, p < 0.001) with greater systolic and diastolic decreases; in the Fujian cohort control at 8 weeks was also higher (81.74% versus 77.39%; adjusted OR 2.43, p = 0.003) with a greater diastolic decrease. Associations were stronger in patients whose blood pressure remained uncontrolled after standardised management, no short-term safety concerns were identified, and the authors themselves describe these results as exploratory associations rather than proof of causal benefit.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

An adjusted odds ratio of 14.56 for a pharmacogenetic effect is not credible: in the Hunan cohort the genotype-guided strategy was bundled with structured management, so the comparison measures a package of care rather than genotype. The Fujian cohort, at 81.74% versus 77.39%, gives the plausible order of magnitude, and it is those four percentage points that the discussion should address. Neither CACNA1C rs2238032 nor CYP3A5 rs776746 is among the validated actionable gene-drug pairs: as it stands, these data justify a dedicated trial, not genotyping before prescribing a calcium channel blocker.

Analysis by Dr Thibaut Benquey